About VBC-GENOMICS Bioscience Research GmbH
VBC-GENOMCIS has been founded in early 1999 and established at the Vienna Biocenter Campus by a core team of
scientists originating from the Institute of Genetics and Microbiology at the University of Vienna. Based on the initial
business focus on providing DNA sequencing and DNA oligonucleotide manufacturing services, VBC GENOMICS has quickly
developed into one of the leading biotech companies in Austria.
Today, the privately financed venture maintains its strong position in the local biotech sector and employs more than
30 members of staff, together with its subsidiary GenoSense Diagnostics.
Already at the beginning, VBC-GENOMICS followed the vision to develop innovative diagnostic tests and procedures based
on unique combinations of novel high-throughput technologies and biological solutions in the genomic, proteomic and
bioinformatics areas. Based on a strong focus on research and development, a number of patents in the area of biochip
technology and molecular diagnostics have been successfully filed and/or granted.
The ISAC (Immuno Solid-phase Allergen Chip) platform developed by VBC-GENOMICS is a revolutionary
approach to the diagnosis of IgE-related Type-I allergic diseases and has the potential to develop in the next gold
standard in allergy diagnosis. With ISAC, the major disease-eliciting allergens can be identified in single step using
only minute amounts of sample material. Consequently, the diagnosis can be based on a comprehensive assessment of
disease-related parameters directly leading to a better treatment as well as to short-, intermediate- and long-term
cost-savings in health provision.
A strong portfolio of collaborations with academia and industry creates the basis for an efficient translation of
visionary ideas into market-ready applications and to guarantee the quality of these products on a long-term. Our aim is
to develop innovative diagnostic tests based on modern high-throughput analytical procedures and powerful bioinformatics
applications, for the benefit of mankind. "VBC-GENOMICS, Future Innovations in Life Science, NOW."
Collaborators:
|
